Beyond current standards: combination therapy and emerging targets in diabetic kidney disease

Article information

Kidney Res Clin Pract. 2026;45(6):912-922
Publication date (electronic) : 2026 August 13
doi : https://doi.org/10.23876/j.krcp.26.234
Jiwon Leeorcid_icon, Mi-Yeon Yuorcid_icon, on behalf of the Korean Diabetic Kidney Disease Study Group
Division of Nephrology, Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Republic of Korea
Correspondence: Mi-Yeon Yu Department of Internal Medicine, Hanyang University Guri Hospital, 153 Gyeongchun-ro, Guri 11923, Republic of Korea. E-mail: pure8203@gmail.com
Received 2026 May 13; Revised 2026 June 16; Accepted 2026 July 4.

Abstract

Diabetic kidney disease continues to be a major contributor to kidney failure and is strongly associated with adverse cardiovascular outcomes. Even with routine use of renin-angiotensin system blockade, many patients show ongoing disease progression, indicating that current treatment alone is often insufficient. Treatment approaches are increasingly focused on combining agents that act through different biological pathways. Among these, sodium-glucose cotransporter 2 inhibitors have taken a central role, supported by consistent evidence for kidney and cardiovascular protection. Their use alongside nonsteroidal mineralocorticoid receptor antagonists, particularly finerenone, has further strengthened this strategy. Glucagon-like peptide-1 receptor agonists are also being incorporated into clinical practice, largely because of their metabolic and vascular effects, although direct evidence for additional kidney benefit remains limited. Interest has also grown in therapies that target pathways not fully addressed by existing drugs. Aldosterone synthase inhibitors reduce aldosterone production at its source, whereas endothelin receptor antagonists act on mechanisms linked to persistent albuminuria and progressive fibrosis. These approaches may help address residual risk in diabetic kidney disease, particularly in patients with persistent albuminuria despite optimized therapy. Data supporting multidrug or triple therapy remain limited. Nonetheless, current evidence suggests that earlier use of combination therapy may offer advantages. Further research is needed to determine how best to integrate these treatments and to confirm their long-term effects on kidney and cardiovascular outcomes.

Introduction

Diabetic kidney disease (DKD) remains the leading cause of end-stage kidney disease worldwide and is a major contributor to cardiovascular morbidity and mortality. Although blockade of the renin-angiotensin system (RAS) has long been the foundation of therapy, its ability to halt disease progression is limited, and a substantial proportion of patients continue to experience worsening kidney function and persistent albuminuria [1,2].

This persistent risk has shifted the therapeutic paradigm away from a single-pathway approach toward strategies that address multiple mechanisms simultaneously. Over the past decade, treatment options have expanded with the introduction of sodium-glucose cotransporter 2 (SGLT2) inhibitors, nonsteroidal mineralocorticoid receptor antagonists (nsMRAs), and glucagon-like peptide-1 (GLP-1) receptor agonists [3–9]. Each of these drug classes targets a different aspect of DKD pathophysiology, and current recommendations from major guidelines increasingly favor their combined use rather than sequential escalation [10–12].

Despite these advances, implementation in routine practice often lags behind, with therapies frequently introduced stepwise and at later stages of disease. As a result, many patients continue to exhibit residual disease activity, reflected by ongoing albuminuria and structural kidney damage. This gap has prompted interest in both earlier combination strategies and additional therapeutic targets that extend beyond currently established pathways. In particular, aldosterone synthase inhibitors (ASIs) and endothelin receptor antagonists (ERAs) have emerged as potential approaches to further attenuate disease progression [13,14].

This review focuses on the evolving role of combination therapy in DKD, with particular emphasis on how multidrug strategies can be used to address persistent disease activity. We also discuss emerging therapeutic approaches, including aldosterone synthase inhibition and endothelin pathway modulation, and consider their potential integration into future treatment frameworks.

Combination therapy in diabetic kidney disease

Rationale for mechanism-based combination therapy

The progression of DKD is driven by a network of interrelated processes rather than a single dominant pathway. Hemodynamic stress within the glomerulus, metabolic disturbances, inflammatory signaling, and progressive fibrosis collectively contribute to sustained kidney injury and loss of function [15,16].

Therapeutic agents currently used in DKD target distinct components of this pathophysiology. SGLT2 inhibitors reduce intraglomerular pressure by restoring tubuloglomerular feedback, whereas nsMRAs attenuate inflammation and fibrosis through mineralocorticoid receptor blockade [3–5,17]. GLP-1 receptor agonists improve metabolic control and provide cardiovascular benefit, while ERAs target vasoconstrictive and profibrotic pathways [18,19].

Because these mechanisms are largely complementary rather than overlapping, therapies targeting different pathways may provide additive benefits when used together. This provides a biological rationale for combination therapy as an approach to reduce residual risk in DKD [1].

SGLT2 inhibitor and finerenone

Among currently available dual-combination strategies in DKD, the combination of an SGLT2 inhibitor and finerenone is supported by converging evidence from large randomized trials, subgroup analyses, and emerging dedicated combination studies. SGLT2 inhibitors and finerenone act through distinct yet complementary mechanisms. SGLT2 inhibitors primarily reduce intraglomerular pressure by restoring tubuloglomerular feedback, whereas finerenone attenuates mineralocorticoid receptor-mediated inflammation and fibrosis. Accordingly, their combination represents a mechanism-based approach to risk reduction rather than simple pharmacologic intensification [3–5].

Initial evidence for this combination derives from subgroup analyses of large randomized trials. In the FIDELIO-DKD and FIGARO-DKD trials, only a minority of patients received background SGLT2 inhibitors; however, the pooled FIDELITY analysis demonstrated that finerenone reduced kidney and cardiovascular outcomes consistently regardless of SGLT2 inhibitor use, with no significant interaction between therapies [20]. These findings support the concept that the two drug classes exert independent and complementary effects. Although exploratory analyses suggested greater reductions in albuminuria with concomitant therapy, these observations were limited by small sample size [20,21].

More direct evidence is provided by the CONFIDENCE trial, the first randomized controlled study specifically designed to evaluate initial combination therapy with finerenone and an SGLT2 inhibitor in patients with chronic kidney disease (CKD) and type 2 diabetes [22]. At 180 days, combination therapy with finerenone and empagliflozin resulted in an approximately 52% reduction in urinary albumin-to-creatinine ratio (UACR) from baseline, which was significantly greater than that achieved with either finerenone alone or empagliflozin alone (additional reductions of 29% and 32%, respectively; p < 0.001 for both comparisons) [23]. This effect was consistent across estimated glomerular filtration rate (eGFR) and albuminuria categories, with 52%–62% relative reductions in albuminuria and more than half of patients achieving a ≥30% decrease in UACR [24]. These findings demonstrate that early combination therapy provides a robust and consistent antiproteinuric effect across a broad spectrum of disease severity.

These findings support true biological additivity. SGLT2 inhibitors primarily target hemodynamic pathways, whereas finerenone modulates non-hemodynamic processes, including inflammation and fibrosis. Simultaneous targeting of these complementary mechanisms results in a greater reduction in albuminuria, a validated surrogate for long-term cardiorenal outcomes [25]. In addition, the rapid onset and consistency of effect suggest that early combination therapy may reduce cumulative albuminuric exposure, an important determinant of long-term risk.

However, several limitations should be acknowledged. The proportion of patients receiving combination therapy in earlier trials was small, and the CONFIDENCE trial evaluated a surrogate endpoint with relatively short follow-up. Long-term outcome data and safety profiles, including the risk of hyperkalemia, remain to be established.

Taken together, current evidence supports the SGLT2 inhibitor-finerenone combination as an effective strategy to reduce residual cardiorenal risk in DKD. This is supported by consistent effects across randomized trials, signals of enhanced albuminuria reduction in subgroup analyses, and direct evidence from dedicated combination studies. In summary, these agents represent complementary and nonredundant therapies, and their combined use is a key component of contemporary DKD management [1,2].

SGLT2 inhibitor and GLP-1 receptor agonist

The combination of an SGLT2 inhibitor and a GLP-1 receptor agonist represents a complementary dual-therapy strategy in DKD. This approach is biologically attractive, although the supporting evidence remains less direct compared with SGLT2 inhibitor-finerenone therapy. These two drug classes act through distinct and largely non-overlapping mechanisms. SGLT2 inhibitors primarily reduce intraglomerular pressure through restoration of tubuloglomerular feedback, whereas GLP-1 receptor agonists provide metabolic, weight-reducing, and anti-inflammatory effects [6,7,26].

Current evidence for this combination is largely indirect and derived from cross-trial and meta-analytic data. In the SMART-C meta-analysis, the cardiovascular and kidney benefits of SGLT2 inhibitors were consistent regardless of background GLP-1 receptor agonist use [27]. Similarly, meta-analyses of GLP-1 receptor agonist trials have demonstrated reductions in major adverse cardiovascular events (approximately 21%) and improvements in eGFR slope, with consistent effects irrespective of concomitant SGLT2 inhibitor use [8]. These findings indicate that the effects of the two drug classes are preserved when used together.

Together, these data support the concept of biological additivity. SGLT2 inhibitors predominantly target intrarenal hemodynamic pathways, whereas GLP-1 receptor agonists exert broader metabolic and vascular effects. Similar findings were observed in both directions, with consistent results in analyses of SGLT2 inhibitor trials according to GLP-1 receptor agonist use and in GLP-1 receptor agonist trials according to SGLT2 inhibitor use. These results suggest that the two drug classes have complementary, rather than overlapping, effects.

Additional support is provided by smaller randomized and observational studies demonstrating greater reductions in glycemic parameters, body weight, and albuminuria with combination therapy compared with either agent alone [28,29]. However, these findings remain limited by sample size and study design, and their impact on long-term kidney outcomes is uncertain.

Several limitations should be considered. Most evidence for combination therapy is derived from subgroup analyses or meta-analyses rather than dedicated randomized trials specifically designed to evaluate dual therapy. In addition, the proportion of patients receiving background combination therapy in major trials has been relatively small, limiting statistical power for interaction analyses. Although consistent effects are observed on surrogate markers such as albuminuria and eGFR slope, definitive evidence for incremental benefit on hard kidney outcomes is still lacking.

Overall, available data suggest that the combination of an SGLT2 inhibitor and a GLP-1 receptor agonist may provide complementary benefits in DKD. Much of the supporting evidence is derived from meta-analyses and cross-trial observations, indicating that the effects of each drug class are largely preserved when used together. Given their distinct actions on intrarenal hemodynamics and systemic metabolic pathways, this combination may offer a broader approach to risk reduction. However, direct evidence for additive effects on long-term kidney outcomes remains limited.

Triple therapy

The concept of triple therapy incorporating an SGLT2 inhibitor, finerenone, and a GLP-1 receptor agonist has emerged from the recognition that substantial residual risk persists despite dual therapy. Rather than representing simple treatment escalation, this approach reflects an effort to concurrently modify multiple determinants of DKD progression, including intraglomerular hemodynamics, mineralocorticoid receptor-mediated inflammation and fibrosis, and systemic metabolic dysfunction [4,18,22].

However, clinical evidence remains indirect. The CONFIDENCE trial demonstrated that initial combination therapy with finerenone and an SGLT2 inhibitor results in a greater reduction in albuminuria compared with either monotherapy [22]. GLP-1 receptor agonists have also shown consistent cardiovascular and kidney benefits, independent of background SGLT2 inhibitor use [18]. Additional support comes from smaller studies and meta-analyses reporting improvements in metabolic parameters and albuminuria with combination therapy, although these data largely reflect dual rather than triple regimens [8,27].

Real-world data indicate that such multidrug regimens are already being used in clinical practice, although in a small proportion of patients. In a recent registry-based analysis, approximately 5% of patients received three or more cardiorenal agents, with a subset treated with even more intensive regimens [30]. Modeling and cross-trial analyses further indicate that combined use of these therapies may substantially reduce cardiovascular and kidney risk, with an estimated hazard ratio of approximately 0.65 for major adverse cardiovascular events compared with conventional care, along with potential benefits for kidney disease progression and survival [2]. Despite these findings, no randomized controlled trial has directly evaluated triple therapy on hard kidney outcomes. Accordingly, available evidence from observational and model-based analyses should be interpreted with caution, given the potential for confounding and selection bias.

At present, triple therapy should be viewed as a promising but unproven strategy. Its use may be reasonable in selected high-risk patients, while awaiting confirmation from dedicated randomized trials. The mechanistic rationale and current clinical evidence for these combination strategies are summarized in Table 1.

Evidence for mechanism-based combination therapy in DKD

Aldosterone synthase inhibitors

Aldosterone pathway modulation: mineralocorticoid receptor antagonist versus aldosterone synthase inhibitor

Aldosterone pathway modulation is emerging as a central therapeutic target in DKD, particularly in the context of persistent residual risk despite optimized RAS blockade and SGLT2 inhibitor therapy [10,11]. Recent advances have expanded the role of aldosterone from a regulator of sodium balance to a key mediator of inflammation, oxidative stress, and fibrosis across the kidney, heart, and vasculature [17,31].

Mineralocorticoid receptor activation plays a central role in DKD progression. Experimental and clinical evidence indicate that mineralocorticoid receptor activation contributes to kidney injury through both epithelial and non-epithelial mechanisms, including podocyte dysfunction, endothelial injury, and fibroblast activation, leading to albuminuria and tubulointerstitial fibrosis [32]. Importantly, these effects may occur independently of systemic blood pressure, highlighting a direct pathogenic role of mineralocorticoid receptor signaling [4,5,17].

Mineralocorticoid receptor activation is not solely dependent on circulating aldosterone levels. Ligand-independent mechanisms, including oxidative stress, Rac1 signaling, hyperglycemia, and local tissue RAS activation, can also drive mineralocorticoid receptor activation [17,32]. Furthermore, aldosterone-mediated injury may persist despite adequate RAS blockade, supporting a role beyond hemodynamic regulation [32].

In this context, the distinction between MRAs and ASIs is clinically important. The complexity of aldosterone signaling and its therapeutic targets are summarized in Fig. 1. Finerenone and other MRAs act by competitively blocking the mineralocorticoid receptor, representing a downstream inhibition strategy, whereas ASIs inhibit aldosterone biosynthesis at the level of cytochrome P450 (CYP) 11B2, providing upstream modulation of aldosterone signaling [13,33,34].

Figure 1.

Differential modulation of aldosterone signaling by MRAs and ASIs in diabetic kidney disease.

Aldosterone production is regulated upstream by the renin-angiotensin system via CYP11B2. Aldosterone exerts its effects through both classical mineralocorticoid receptor-mediated genomic pathways and rapid non-genomic signaling pathways. In addition to ligand-dependent activation, mineralocorticoid receptor signaling can be driven by ligand-independent mechanisms, including oxidative stress, hyperglycemia, cortisol, and Rac1-mediated pathways. ASIs reduce aldosterone production by inhibiting CYP11B2, thereby attenuating ligand-dependent activation. In contrast, MRAs directly block receptor-level signaling and may more effectively inhibit downstream effects, including those driven by ligand-independent activation. GPER-related signaling represents an additional pathway contributing to non-genomic aldosterone effects. Together, these mechanisms highlight the complementary roles of ASIs and MRAs in modulating aldosterone signaling in diabetic kidney disease.

ASI, aldosterone synthase inhibitor; GPER1, G protein-coupled estrogen receptor 1; MRA, mineralocorticoid receptor antagonist.

This distinction is particularly relevant in the setting of “aldosterone breakthrough,” in which aldosterone levels re-increase during chronic angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker therapy [35]. This phenomenon may occur through multiple mechanisms, including alternative receptor signaling, epigenetic reactivation of CYP11B2, and potassium-mediated stimulation of aldosterone synthesis. As a result, persistent aldosterone activity may continue to drive inflammation and fibrosis despite apparent RAS suppression.

Accordingly, while MRAs effectively block receptor-level signaling, they do not suppress aldosterone production or fully inhibit ligand-independent mineralocorticoid receptor activation. In contrast, ASIs directly reduce circulating aldosterone levels and may more effectively target upstream drivers of mineralocorticoid receptor activation.

Thus, MRAs and ASIs should be viewed as complementary rather than competing strategies, representing downstream receptor blockade and upstream hormone synthesis inhibition, respectively [13,33,34].

Aldosterone synthase inhibitors

ASIs target the final enzymatic step in aldosterone biosynthesis via selective inhibition of CYP11B2 [13,33]. By reducing aldosterone production at its source, this approach enables upstream modulation of mineralocorticoid receptor signaling and may complement receptor blockade, particularly in conditions characterized by aldosterone excess or dysregulation [12,32,33].

Aldosterone contributes to kidney injury through multiple pathways, including inflammation, oxidative stress, and fibrosis [32,35]. These effects are not solely dependent on circulating hormone levels, as mineralocorticoid receptor activation can persist despite conventional RAS blockade. In this context, suppression of aldosterone synthesis represents a potential strategy to further attenuate residual disease activity.

Clinical development of ASIs has primarily focused on hypertension. In the BrigHTN trial, baxdrostat significantly reduced systolic blood pressure in patients with treatment-resistant hypertension [36]. Similarly, lorundrostat demonstrated clinically meaningful blood pressure reductions across phase 2 and 3 studies [37]. Although some studies have explored kidney-related parameters, these were not primary endpoints, and direct evidence in DKD populations remains limited.

Nevertheless, these findings have potential implications for DKD. Relative aldosterone excess and mineralocorticoid receptor overactivation are frequently observed in patients with DKD, even in the absence of overt primary aldosteronism [32,33]. Accordingly, targeting aldosterone synthesis may represent a rational strategy to address residual risk beyond conventional RAS blockade. Beyond blood pressure reduction, aldosterone plays a central role in inflammation, fibrosis, and kidney injury. Experimental and clinical studies have shown that aldosterone promotes glomerular injury, podocyte dysfunction, and tubulointerstitial fibrosis through both genomic and non-genomic pathways [17,32,35]. Clinical studies in albuminuric CKD populations, including cohorts predominantly composed of patients with type 2 diabetes, further support the role of aldosterone-driven signaling in kidney injury [38]. However, current evidence remains largely mechanistic, as definitive renal outcome trials are not yet available.

Several limitations should be considered. Long-term renal and cardiovascular outcome data are not yet available, and the role of ASIs in DKD has not been established in randomized controlled trials. Hyperkalemia remains a potential concern, particularly in patients with advanced CKD or concomitant RAS inhibition. In addition, ASIs do not address ligand-independent mineralocorticoid receptor activation, which may persist under conditions of oxidative stress and metabolic dysfunction [32,35].

ASIs should be regarded as emerging adjunctive therapies rather than replacements for established treatment. Their potential role lies in complementing receptor-level blockade and targeting upstream drivers of mineralocorticoid signaling in DKD.

Clinical implications in diabetic kidney disease

From a clinical perspective, ASIs may be particularly relevant in patients with DKD who have persistent albuminuria despite optimized therapy with RAS blockade and SGLT2 inhibitors, especially in the setting of suspected aldosterone breakthrough or intolerance to MRAs. In addition, newer agents demonstrate improved selectivity for CYP11B2 over CYP11B1, which may reduce the risk of cortisol suppression and improve tolerability [13].

At present, these agents are positioned as part of a combination-based strategy, with their role to be defined by ongoing outcome trials.

Endothelin receptor antagonists: proteinuria-centered strategy

Endothelin-1 in diabetic kidney disease pathogenesis

ERAs are being investigated in DKD based on the pathogenic role of endothelin-1 in kidney injury. Although endothelin-1 is a potent vasoconstrictor, its biological effects extend to the promotion of inflammation, oxidative stress, and fibrosis, contributing to both glomerular and tubulointerstitial damage. These effects are primarily mediated through endothelin A receptor activation, whereas endothelin B receptor signaling exerts protective actions, including natriuresis and maintenance of endothelial function. This receptor-specific divergence provides the rationale for selective endothelin A blockade as a therapeutic strategy [19,39].

In patients with diabetes, endothelin-1 levels tend to be elevated and are influenced by several metabolic factors, including hyperglycemia, insulin resistance, and obesity. Activation of the RAS further increases its expression. Within the kidney, endothelin-1 is produced locally by glomerular endothelial cells, mesangial cells, and podocytes, suggesting that intrarenal signaling plays a meaningful role in disease progression [19,39].

At the level of the glomerulus, endothelin-1 disrupts barrier function by increasing permeability and promoting podocyte injury, which contributes to proteinuria. It also affects mesangial cells by inducing contraction and matrix expansion, leading to a gradual loss of filtration surface area. These structural changes are accompanied by progressive glomerulosclerosis [39]. In addition, endothelin signaling interacts with the RAS, reinforcing intraglomerular hypertension and inflammatory activity, which are central to DKD progression [19,39].

Proof-of-concept: blood pressure-independent antiproteinuric effect

Early clinical studies helped clarify the potential role of endothelin blockade in kidney disease. In patients with proteinuric CKD, selective endothelin A receptor antagonism reduced proteinuria and arterial stiffness independent of blood pressure lowering [40]. These observations suggest that endothelin signaling directly contributes to kidney injury and that its blockade may exert disease-modifying effects beyond hemodynamic changes.

ASCEND study: signal and limitation

The ASCEND trial evaluated the selective endothelin A receptor antagonist avosentan in patients with type 2 diabetes and overt nephropathy. The study was stopped early because of safety concerns, but it provided important information on both the efficacy and limitations of endothelin blockade. Avosentan demonstrated a significant 44%–49% reduction in albuminuria, supporting the role of endothelin signaling in kidney injury [41]. However, this effect was accompanied by a higher incidence of fluid-related adverse events, including edema and heart failure, which ultimately limited its clinical use.

These adverse effects are closely related to the physiological role of endothelin receptors in the kidney. Fluid retention associated with ERAs is partly attributed to impaired endothelin B-mediated natriuresis, which leads to sodium and water retention [19]. In the collecting duct, endothelin B receptor activation promotes sodium excretion by inhibiting epithelial sodium channels. Interference with this pathway can reduce natriuresis and lead to sodium and fluid retention [39]. Although avosentan selectively targets endothelin A receptors, this does not fully prevent fluid-related complications, as endothelin A receptors also contribute to vascular tone and sodium handling within the kidney [14].

The experience of the ASCEND trial underscored a fundamental therapeutic trade-off in the management of DKD: achieving meaningful renal protection while limiting the risk of fluid overload and heart failure. In that study, the use of relatively high doses of avosentan (25–50 mg) was associated with an increased incidence of adverse events, suggesting a dose-dependent relationship between endothelin receptor blockade and sodium and water retention. These findings raised the possibility that lower, more selective dosing strategies might retain antiproteinuric efficacy while improving tolerability.

These findings have influenced subsequent therapeutic strategies. Current approaches focus on lower dosing of ERAs and on combination therapy, particularly with SGLT2 inhibitors. This strategy is supported by the natriuretic and diuretic effects of SGLT2 inhibition, which may offset fluid retention while preserving the antiproteinuric effects of endothelin blockade [1].

SONAR trial: refinement through patient selection

The SONAR (Study of Diabetic Nephropathy with Atrasentan) trial was designed to address the limitations observed in ASCEND, particularly those related to fluid retention and dosing. Rather than questioning the efficacy of ERAs, the ASCEND experience highlighted the need for concise patient selection and risk control [41]. SONAR was therefore designed to preserve the antiproteinuric benefits of endothelin blockade while mitigating these risks through systematic patient selection [42,43].

Before entering the enrichment phase, patients with a history of heart failure or a baseline B-type natriuretic peptide (BNP) level greater than 200 pg/mL were excluded. Eligible participants then received open-label atrasentan 0.75 mg once daily for 6 weeks. Patients with a UACR reduction of at least 30% were classified as responders, whereas a subset of those with a reduction of less than 30% was randomized in a separate nonresponder stratum. Participants were not eligible for randomization if, during the enrichment phase, body weight increased by more than 3 kg in conjunction with a BNP level of at least 300 pg/mL, or if serum creatinine increased by both more than 20% and more than 0.5 mg/dL.

During the run-in phase, albuminuria was reduced by approximately 50%. In the randomized phase, atrasentan was associated with a lower risk of kidney outcomes, including doubling of serum creatinine or progression to end-stage kidney disease (hazard ratio, 0.65; 95% confidence interval, 0.49–0.88). Although fluid-related adverse events were still observed, the incidence of serious heart-failure–related outcomes was lower than that reported in ASCEND, reflecting improved risk mitigation through patient selection and monitoring.

Further analyses indicated that treatment effects were generally consistent across subgroups, while patients with a strong early reduction in albuminuria derived the greatest benefit. In contrast, individuals with features suggestive of volume sensitivity were excluded, underscoring the importance of volume status in determining both efficacy and safety.

Overall, SONAR extends the findings of ASCEND by showing that the clinical utility of ERAs depends on appropriate patient selection. These results support a more individualized approach, in which early response and tolerability are used to guide treatment decisions and to balance efficacy with safety in patients with DKD, consistent with current guideline recommendations [10,44].

ZENITH-CKD trial: endothelin receptor antagonist in combination therapy

The ZENITH-CKD trial evaluated the addition of the selective ERA zibotentan to dapagliflozin in patients with CKD, of whom approximately 58% had type 2 diabetes, providing clinically relevant insights for DKD populations. In this phase 2b randomized trial, combination therapy resulted in a reduction in UACR of approximately 30%–40% compared with dapagliflozin alone, with an acceptable safety profile [45]. Importantly, subsequent analyses demonstrated that this antiproteinuric effect was consistent in patients with and without diabetes, supporting the applicability of endothelin receptor antagonism to DKD, where albuminuria is a key driver of disease progression [46].

Further analyses provided insight into the safety profile of this approach. The risk of fluid retention with ERAs increased with higher drug exposure and declining kidney function. However, concomitant treatment with dapagliflozin appeared to mitigate this effect, a finding of particular relevance in DKD, where volume overload and heart failure risk are common clinical concerns [47]. This interaction is consistent with their physiological effects. SGLT2 inhibitors promote natriuresis and osmotic diuresis, which may offset the sodium- and fluid-retentive properties of ERAs, thereby improving the therapeutic window of ERA therapy in patients with DKD.

These findings suggest that ERAs may have a role in patients with DKD who have persistent albuminuria despite optimized RAS blockade and SGLT2 inhibitor therapy, a clinical scenario frequently encountered in advanced DKD.

Clinical implications in diabetic kidney disease

From a clinical perspective, ERAs may be considered in patients with DKD who have persistent albuminuria despite optimized therapy with RAS blockade and SGLT2 inhibitors. Their use requires careful patient selection because of the risk of fluid retention, particularly in those with advanced CKD or underlying cardiac disease.

In this setting, ERAs are best viewed as adjunctive agents within combination therapy, with their clinical utility likely to depend on individualized risk assessment and the use of concomitant therapies to improve tolerability.

Conclusion

The management of DKD has evolved beyond a purely stepwise approach toward strategies that address multiple pathways involved in disease progression. SGLT2 inhibitor-based regimens, particularly in combination with finerenone, are now widely used to reduce residual cardiorenal risk.

Additional therapies are being explored to address mechanisms not fully targeted by current treatment. ASIs and ERAs act on distinct biological pathways relevant to persistent albuminuria and progressive kidney injury.

Although more intensive combination strategies are of increasing interest, current evidence remains limited and is largely derived from indirect or early-phase studies. Further randomized controlled trials are needed to define their role and to establish long-term efficacy and safety.

In clinical practice, a combination-based approach may be considered in selected high-risk patients with persistent disease activity despite standard therapy.

Notes

Conflicts of interest

All authors have no conflicts of interest to declare.

Funding

This work was supported by the research fund of Hanyang University (HY-202100000001475).

Data sharing statement

Data sharing is not applicable to this article because no datasets were generated or analyzed during the current study.

Authors’ contributions

Conceptualization, Supervision: MYY

Investigation, Resources: All authors

Writing–original draft: All authors

Writing–review & editing: All authors

All authors read and approved the final manuscript.

References

1. Alicic RZ, Neumiller JJ, Tuttle KR. Combination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease. Nephrol Dial Transplant 2025;40(Supplement 1):i3–i17. 10.1093/ndt/gfae212. 39907543.
2. Neuen BL, Heerspink HJL, Vart P, et al. Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria. Circulation 2024;149:450–462. 10.1161/circulationaha.123.067584.
3. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020;383:1436–1446. 10.1056/nejmoa2024816. 32970396.
4. Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020;383:2219–2229. 10.1056/nejmoa2025845. 33264825.
5. Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 2021;385:2252–2263. 10.1056/nejmoa2110956. 34449181.
6. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet 2019;394:131–138. 10.1016/S0140-6736(19)31150-X. 31189509.
7. Mann JF, Ørsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017;377:839–848. 10.1056/nejmoa1616011. 28854085.
8. Neuen BL, Fletcher RA, Heath L, et al. Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis. Circulation 2024;150:1781–1790. 10.1161/circulationaha.124.071689. 39210781.
9. Pan HC, Wang CA, Chen JY, Wu VC. Medical treatment for diabetic acute kidney disease from 2012 to 2024: advances, prescription trends, and future directions. Kidney Res Clin Pract 2026;45:327–342. 10.23876/j.krcp.25.126.
10. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2024;105(4S):S117–S314. 10.1016/j.kint.2023.10.018. 38490803.
11. American Diabetes Association Professional Practice Committee. Summary of revisions: standards of care in diabetes-2025. Diabetes Care 2025;48(1 Suppl 1):S6–S13. 10.2337/dc25-SREV. 39651984.
12. Tong LL, Adler SG. Diabetic kidney disease treatment: new perspectives. Kidney Res Clin Pract 2022;41(Suppl 2):S63–S73. 10.23876/j.krcp.21.288. 36239062.
13. Patel SK, Teoh H, Saunthar A, Yau TM, Verma S. The emerging role of aldosterone synthase inhibitors in overcoming renin-angiotensin-aldosterone system therapy limitations: a narrative review. Card Fail Rev 2025;11e20. 10.15420/cfr.2025.09. 40901557.
14. Chung EY, Badve SV, Heerspink HJ, Wong MG. Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond? Nephrology (Carlton) 2023;28:97–108. 10.1111/nep.14130. 36350038.
15. Maruno S, Tanaka T, Nangaku M. Exploring molecular targets in diabetic kidney disease. Kidney Res Clin Pract 2022;41(Suppl 2):S33–S45. 10.23876/j.krcp.21.251. 35354246.
16. Pak ES, Cha JJ, Cha DR, Kanasaki K, Ha H. Adenosine receptors as emerging therapeutic targets for diabetic kidney disease. Kidney Res Clin Pract 2022;41(Suppl 2):S74–S88. 10.23876/j.krcp.22.011. 36239063.
17. Jaisser F, Farman N. Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology. Pharmacol Rev 2016;68:49–75. 10.1124/pr.115.011106. 26668301.
18. Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 2024;391:109–121. 10.1056/nejmoa2403347. 38785209.
19. Kohan DE, Barton M. Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int 2014;86:896–904. 10.1038/ki.2014.143. 24805108.
20. Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 2022;43:474–484. 10.1093/eurheartj/ehab777. 35023547.
21. Filippatos G, Anker SD, Agarwal R, et al. Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. Circulation 2021;143:540–552. 10.1161/circulationaha.120.051898. 33198491.
22. Agarwal R, Green JB, Heerspink HJ, et al. COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics. Nephrol Dial Transplant 2025;40:1559–1569. 10.1093/ndt/gfaf022. 39916475.
23. Agarwal R, Green JB, Heerspink HJ, et al. Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes. N Engl J Med 2025;393:533–543. 10.1056/nejmoa2410659. 40470996.
24. Vaduganathan M, Green JB, Heerspink HJ, et al. Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial. Nephrol Dial Transplant 2025;41:161–170. 10.1093/ndt/gfaf160. 40886054.
25. Mottl A, Scott C, Green JB, et al. Baseline kidney function, albuminuria, and urine albumin-creatinine ratio reduction with finerenone, empagliflozin, or both: post hoc analyses of CONFIDENCE trial. J Am Soc Nephrol 2026;37:764–776.
26. Muskiet MH, Tonneijck L, Smits MM, et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat Rev Nephrol 2017;13:605–628. 10.1038/nrneph.2017.123. 28869249.
27. Apperloo EM, Neuen BL, Fletcher RA, et al. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 2024;12:545–557. 10.1016/s2213-8587(24)00155-4. 38991584.
28. DeFronzo RA. Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. Diabetes Obes Metab 2017;19:1353–1362. 10.1111/dom.12982. 28432726.
29. van Ruiten CC, van der Aart-van der Beek AB, IJzerman RG, et al. Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: a prespecified secondary analysis of a randomized controlled clinical trial. Diabetes Obes Metab 2021;23:1851–1858. 10.1111/dom.14410. 33908691.
30. Lan NS, McFadden B, Johnson A, et al. Real-world prescribing of renal and cardiovascular protective drugs in patients with type 2 diabetes and chronic kidney disease: analysis of data from a Western Australian quaternary hospital. Heart Lung Circ 2025;34:1089–1097. 10.1016/j.hlc.2025.07.007. 40912924.
31. Epstein M. Aldosterone and mineralocorticoid receptor signaling as determinants of cardiovascular and renal injury: from Hans Selye to the present. Am J Nephrol 2021;52:209–216. 10.1159/000515622. 33857953.
32. Epstein M, Kovesdy CP, Clase CM, Sood MM, Pecoits-Filho R. Aldosterone, mineralocorticoid receptor activation, and CKD: a review of evolving treatment paradigms. Am J Kidney Dis 2022;80:658–666. 10.1053/j.ajkd.2022.04.016. 36057467.
33. Brown JM, Siddiqui M, Calhoun DA, et al. The unrecognized prevalence of primary aldosteronism: a cross-sectional study. Ann Intern Med 2020;173:10–20. 10.7326/M20-0065. 32449886.
34. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003;41:64–68. 10.1161/01.hyp.0000044937.95080.e9. 12511531.
35. Mogi M. Aldosterone breakthrough from a pharmacological perspective. Hypertens Res 2022;45:967–975. 10.1038/s41440-022-00913-4. 35422512.
36. Kida Y. Baxdrostat for treatment-resistant hypertension. N Engl J Med 2023;388:1820. 10.1056/nejmc2302673.
37. Laffin LJ, Kopjar B, Melgaard C, et al. Lorundrostat efficacy and safety in patients with uncontrolled hypertension. N Engl J Med 2025;392:1813–1823. 10.1056/nejmoa2501440. 40267417.
38. Dwyer JP, Maklad N, Vedin O, et al. Efficacy and safety of baxdrostat in participants with CKD and uncontrolled hypertension: a randomized, double-blind, placebo-controlled trial. J Am Soc Nephrol 2026;37:299–311. 10.1681/ASN.0000000849. 40913594.
39. Schiffrin EL, Pollock DM. Endothelin system in hypertension and chronic kidney disease. Hypertension 2024;81:691–701. 10.1161/hypertensionaha.123.21716. 38059359.
40. Dhaun N, Macintyre IM, Melville V, et al. Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-A receptor antagonism in chronic kidney disease. Hypertension 2009;54:113–119. 10.1161/hypertensionaha.109.132670. 19506099.
41. Mann JF, Green D, Jamerson K, et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010;21:527–535. 10.1681/asn.2009060593. 20167702.
42. Heerspink HJ, Parving HH, Andress DL, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet 2019;393:1937–1947. 10.1016/S0140-6736(19)30772-X. 30995972.
43. Heerspink HJ, Andress DL, Bakris G, et al. Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: a clinical trial design novel to diabetic nephropathy. Diabetes Obes Metab 2018;20:1369–1376. 10.1111/dom.13245. 29405626.
44. American Diabetes Association Professional Practice Committee for Diabetes. 11. Chronic kidney disease and risk management: standards of care in diabetes-2026. Diabetes Care 2026;49(Suppl 1):S246–S260. 10.2337/dc26-S011. 41358881.
45. Heerspink HJ, Kiyosue A, Wheeler DC, et al. Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial. Lancet 2023;402:2004–2017. 10.1016/s0140-6736(23)02230-4. 37931629.
46. Wasehuus V, Smeijer JD, Ambery P, et al. Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone in patients with diabetic and non-diabetic chronic kidney disease. Diabetes Obes Metab 2025;27:4311–4319. 10.1111/dom.16468. 40396470.
47. Smeijer JD, Wasehuus VS, Dhaun N, et al. Effects of zibotentan alone and in combination with dapagliflozin on fluid retention in patients with CKD. J Am Soc Nephrol 2024;35:1381–1390. 10.1681/asn.0000000000000436. 39352861.

Article information Continued

Figure 1.

Differential modulation of aldosterone signaling by MRAs and ASIs in diabetic kidney disease.

Aldosterone production is regulated upstream by the renin-angiotensin system via CYP11B2. Aldosterone exerts its effects through both classical mineralocorticoid receptor-mediated genomic pathways and rapid non-genomic signaling pathways. In addition to ligand-dependent activation, mineralocorticoid receptor signaling can be driven by ligand-independent mechanisms, including oxidative stress, hyperglycemia, cortisol, and Rac1-mediated pathways. ASIs reduce aldosterone production by inhibiting CYP11B2, thereby attenuating ligand-dependent activation. In contrast, MRAs directly block receptor-level signaling and may more effectively inhibit downstream effects, including those driven by ligand-independent activation. GPER-related signaling represents an additional pathway contributing to non-genomic aldosterone effects. Together, these mechanisms highlight the complementary roles of ASIs and MRAs in modulating aldosterone signaling in diabetic kidney disease.

ASI, aldosterone synthase inhibitor; GPER1, G protein-coupled estrogen receptor 1; MRA, mineralocorticoid receptor antagonist.

Table 1.

Evidence for mechanism-based combination therapy in DKD

Combination strategy Targeted pathways Mechanistic complementarity Clinical implication Clinical evidence
SGLT2i + finerenone Hemodynamic + inflammation/fibrosis Reduction of intraglomerular pressure combined with attenuation of MR-mediated inflammation and fibrosis Best-supported combination; consistent additive antiproteinuric effect [23–25]
SGLT2i + GLP-1RA Hemodynamic + metabolic/inflammatory Renal hemodynamic modulation combined with systemic metabolic and vascular effects Additive cardiometabolic benefit; renal benefit supported but indirect [8,27,29]
SGLT2i + ERA Hemodynamic + endothelin-mediated vasoconstriction and fibrosis SGLT2i-induced natriuresis may offset ERA-associated sodium retention Early-phase combination data support potential benefit; careful monitoring for fluid retention is required [45–47]
Triple therapy (SGLT2i + finerenone + GLP-1RA) Hemodynamic + fibrosis + metabolic Simultaneous targeting of multiple complementary pathways involved in DKD progression No dedicated clinical trial; indirect support from component trials and real-world data [2,30]; currently hypothesis-generating -

Key clinical evidence includes studies that directly evaluated combination therapy, including randomized controlled trials (RCTs), post hoc analyses, and meta-analyses. RCT evidence is indicated by underlined and bold reference numbers. Triple therapy is not supported by direct RCT evidence; available data are derived from indirect and real-world observations.

DKD, diabetic kidney disease; ERA, endothelin receptor antagonist; GLP-1RA, glucagon-like peptide-1 receptor agonist; MR, mineralocorticoid receptor; SGLT2i, sodium-glucose cotransporter 2 inhibitor.